The Proopiomelanocortin Gene
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Oxytocin Is an Anabolic Bone Hormone
Oxytocin is an anabolic bone hormone Roberto Tammaa,1, Graziana Colaiannia,1, Ling-ling Zhub, Adriana DiBenedettoa, Giovanni Grecoa, Gabriella Montemurroa, Nicola Patanoa, Maurizio Strippolia, Rosaria Vergaria, Lucia Mancinia, Silvia Coluccia, Maria Granoa, Roberta Faccioa, Xuan Liub, Jianhua Lib, Sabah Usmanib, Marilyn Bacharc, Itai Babc, Katsuhiko Nishimorid, Larry J. Younge, Christoph Buettnerb, Jameel Iqbalb, Li Sunb, Mone Zaidib,2, and Alberta Zallonea,2 aDepartment of Human Anatomy and Histology, University of Bari, 70124 Bari, Italy; bThe Mount Sinai Bone Program, Mount Sinai School of Medicine, New York, NY 10029; cBone Laboratory, The Hebrew University of Jerusalem, Jerusalem 91120, Israel; dGraduate School of Agricultural Science, Tohoku University, Aoba-ku, Sendai, Miyagi 981-8555 Japan; and eCenter for Behavioral Neuroscience, Department of Psychiatry, Emory University School of Medicine, Atlanta, GA 30322 Communicated by Maria Iandolo New, Mount Sinai School of Medicine, New York, NY, February 19, 2009 (received for review October 24, 2008) We report that oxytocin (OT), a primitive neurohypophyseal hor- null mice (5). But the mice are not rendered diabetic, and serum mone, hitherto thought solely to modulate lactation and social glucose homeostasis remains unaltered (9). Thus, whereas the bonding, is a direct regulator of bone mass. Deletion of OT or the effects of OT on lactation and parturition are hormonal, actions OT receptor (Oxtr) in male or female mice causes osteoporosis that mediate appetite and social bonding are exerted centrally. resulting from reduced bone formation. Consistent with low bone The precise neural networks underlying OT’s central effects formation, OT stimulates the differentiation of osteoblasts to a remain unclear; nonetheless, one component of this network mineralizing phenotype by causing the up-regulation of BMP-2, might be the interactions between leptin- and OT-ergic neurones which in turn controls Schnurri-2 and 3, Osterix, and ATF-4 expres- in the hypothalamus (10). -
Neuroendocrinology 165P PC125 EFFECT of CALCITONIN GENE
Poster Communication - Neuroendocrinology 165P PC125 PC127 EFFECT OF CALCITONIN GENE-RELATED PEPTIDE ON Effects of the potent hop-derived phytoestrogen, GnRH mRNA EXPRESSION IN THE GT1-7 CELL 8-prenylnaringenin, on the reproductive neuroendocrine axis 1 1 1 2 1 J. Kinsey-Jones ,X.Li ,J.Bowe ,S.Brain and K. O’Byrne J. Bowe1,J.Kinsey-Jones1,X.Li1,S.Brain2 and K. O’Byrne1 1Division of Reproductive Health, Endocrinology and Development, 1Division of Reproductive Health, Endocrinology and Development, Kings College London, London, UK and 2Centre for Cardiovascular King’s College London, London, UK and 2Centre for Cardiovascular Biology, Kings College London, London, UK Biology, King’s College London, London, UK Calcitonin gene-related peptide (CGRP) has recently been The phytoestrogen, 8-prenylnaringenin (8-PN), is the most potent shown to induce a profound suppression of the hypothala- phytoestrogen discovered to date. Derived from hops, it is pres- mic gonadotrophin-releasing hormone (GnRH) pulse gen- ent in dietary supplements currently marketed for natural breast erator, resulting in an inhibition of pulsatile luteinising hor- enhancement, though little is known about efficacy rates or other mone (LH) secretion in the rat (Li et al., 2004). The aims of effects (Coldham & Sauer, 2001). 8-PN is also of potential inter- the present study were, (i) to determine the presence of the est in the treatment of menopausal symptoms and diseases involv- CGRP receptor subunits, receptor activity modifying protein- ing angiogenesis. It is known that various phytoestrogens pro- 1(RAMP-1) and calcitonin receptor like receptor (CL), both duce inhibitory effects on gonadotrophin secretion in both of which are required for functional activity, in the GT1-7 humans and animals (McGarvey et al, 2001). -
Injection Safely and Effectively
HIGHLIGHTS OF PRESCRIBING INFORMATION ---------------------DOSAGE FORMS AND STRENGTHS---------------------- These highlights do not include all the information needed to use MIACALCIN injection safely and effectively. See full prescribing Injection: 200 International Units per mL sterile solution in 2 mL multi- information for MIACALCIN injection. dose vials (3) MIACALCIN® (calcitonin-salmon) injection, synthetic, for subcutaneous ----------------------------CONTRAINDICATIONS------------------------------ or intramuscular use Hypersensitivity to calcitonin-salmon or any of the excipients (4) Initial U.S. Approval: 1975 -----------------------WARNINGS AND PRECAUTIONS------------------------ -------------------------------RECENT MAJOR CHANGES----------------------- Serious hypersensitivity reactions, including reports of fatal anaphylaxis Indications and Usage (1.4) 03/2014 have been reported. Consider skin testing prior to treatment in patients with Warnings and Precautions (5.3) 03/2014 suspected hypersensitivity to calcitonin-salmon (5.1) ----------------------------INDICATIONS AND USAGE--------------------------- Hypocalcemia has been reported. Ensure adequate intake of calcium and vitamin D (5.2) Miacalcin synthetic injection is a calcitonin, indicated for the following Malignancy: A meta-analysis of 21 clinical trials suggests an increased risk conditions: of overall malignancies in calcitonin-salmon-treated patients (5.3, 6.1) Treatment of symptomatic Paget’s disease of bone when alternative Circulating antibodies to calcitonin-salmon -
Regulatory Mechanisms of Somatostatin Expression
International Journal of Molecular Sciences Review Regulatory Mechanisms of Somatostatin Expression Emmanuel Ampofo * , Lisa Nalbach, Michael D. Menger and Matthias W. Laschke Institute for Clinical & Experimental Surgery, Saarland University, 66421 Homburg/Saar, Germany; [email protected] (L.N.); [email protected] (M.D.M.); [email protected] (M.W.L.) * Correspondence: [email protected]; Tel.: +49-6841-162-6561; Fax: +49-6841-162-6553 Received: 25 May 2020; Accepted: 9 June 2020; Published: 11 June 2020 Abstract: Somatostatin is a peptide hormone, which most commonly is produced by endocrine cells and the central nervous system. In mammals, somatostatin originates from pre-prosomatostatin and is processed to a shorter form, i.e., somatostatin-14, and a longer form, i.e., somatostatin-28. The two peptides repress growth hormone secretion and are involved in the regulation of glucagon and insulin synthesis in the pancreas. In recent years, the processing and secretion of somatostatin have been studied intensively. However, little attention has been paid to the regulatory mechanisms that control its expression. This review provides an up-to-date overview of these mechanisms. In particular, it focuses on the role of enhancers and silencers within the promoter region as well as on the binding of modulatory transcription factors to these elements. Moreover, it addresses extracellular factors, which trigger key signaling pathways, leading to an enhanced somatostatin expression in health and disease. Keywords: somatostatin; pre-prosomatostatin; δ-cells; central nervous system (CNS); gut; hypothalamus; cAMP resonse element (CRE); pancreas/duodenum homeobox protein (PDX)1; paired box protein (PAX)6; growth hormone (GH); brain-derived neurotrophic factor (BDNF); glutamateric system; pancreas 1. -
(Calcitonin-Salmon) Nasal Spray, for Intranasal Use Vitamin D (5.2) Initial U.S
HIGHLIGHTS OF PRESCRIBING INFORMATION -------------------------- WARNINGS AND PRECAUTIONS ---------------------- These highlights do not include all the information needed to use • Serious hypersensitivity reactions including anaphylactic shock have been MIACALCIN nasal spray safely and effectively. See full prescribing reported. Consider skin testing prior to treatment in patients with information for MIACALCIN nasal spray. suspected hypersensitivity to calcitonin-salmon (5.1) • Hypocalcemia has been reported. Ensure adequate intake of calcium and MIACALCIN® (calcitonin-salmon) nasal spray, for intranasal use vitamin D (5.2) Initial U.S. Approval: 1975 • Nasal adverse reactions, including severe ulceration can occur. Periodic nasal examinations are recommended (5.3) • Malignancy: A meta-analysis of 21 clinical trials suggests an increased ------------------------------ INDICATIONS AND USAGE --------------------------- risk of overall malignancies in calcitonin-salmon-treated patients (5.4, Miacalcin nasal spray is a calcitonin, indicated for the treatment of 6.1) postmenopausal osteoporosis in women greater than 5 years postmenopause • Circulating antibodies to calcitonin-salmon may develop, and may cause when alternative treatments are not suitable. Fracture reduction efficacy has not loss of response to treatment (5.5) been demonstrated (1.1) ------------------------------- ADVERSE REACTIONS ------------------------------- Limitations of Use: Most common adverse reactions (3% or greater) are rhinitis, epistaxis and other • Due to the possible association between malignancy and calcitonin nasal symptoms, back pain, arthralgia, and headache (6) salmon use, the need for continued therapy should be re-evaluated on a periodic basis (1.2, 5.4) To report SUSPECTED ADVERSE REACTIONS, contact Mylan • Miacalcin nasal spray has not been shown to increase bone mineral Pharmaceuticals Inc. at 1-877-446-3679 (1-877-4-INFO-RX) or FDA at 1 density in early postmenopausal women (1.2) 800-FDA-1088 or www.fda.gov/medwatch. -
Plasma Somatostatin and Cholecystokinin Levels in Preterm Infants and Their Mothers at Birth
0031-399819513706-0771$03.0010 PEDIATRIC RESEARCH Vol. 37, No. 6, 1995 Copyright O 1995 International Pediatric Research Foundation, Inc Printed in U.S.A. Plasma Somatostatin and Cholecystokinin Levels in Preterm Infants and Their Mothers at Birth C.-J. TORNHAGE, F. SERENIUS, K. UVNAS-MOBERG,AND T. LINDBERG Department of Pediatrics, UmeB University, UmeB [C.-J.T., F.S., T.L.] and Department of Pharmacology, Karolinska Institute, Stockholm, Sweden [K. U-M.] Regulatory gut peptides play an important role in regulating same. They were also independent of sex, birth weight, gesta- the gastrointestinal tract. Our knowledge about the pattern of tional age, umbilical cord blood pH, or glucose level. In mothers, secretion and function of these peptides is scanty in preterm but not in infants, plasma SS levels were higher after vaginal infants. Therefore, plasma somatostatin (SS) and cholecystokinin delivery than after cesarean section. After multiple birth, new- (CCK) levels were estimated just after birth in 65 mothers and 73 born plasma SS, but not plasma CCK, was significantly lower preterm infants (umbilical cord blood). The gestational age was than after single birth (9.1 + 7.7 versus 16.9 2 12.7 pmol/L). 32 (24-36 median ranges) wk and birth weight 1900 (475-3350) (Pediatr Res 37: 771-776, 1995) g. The umbilical cord blood pH was 7.32 + 0.10 (mean t- SD). After Sep-Pak-C,, semichromatography of plasma, SS and CCK Abbreviations were analyzed by RIA. Both plasma SS and CCK levels were SS, somatostatin significantly higher in infants than in mothers (SS = 14.5 i. -
Transition from Biological to Chemical Assay for Quality Assurance of Medicinal Substances (Apis) and Formulated Preparations
WHO/BS/07.2070 ENGLISH ONLY EXPERT COMMITTEE ON BIOLOGICAL STANDARDIZATION Geneva - 8 to 12 October 2007 Discussion paper: Transition from biological to chemical assay for quality assurance of medicinal substances (APIs) and formulated preparations A Bristow National Institute for Biological Standards and Control, Blanche Lane, South Mimms, Potters Bar, Herts EN6 3QG, UK ML Rabouhans, J Joung, DJ Wood World Health Organization, Geneva, Switzerland © World Health Organization 2007 All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected] ). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: [email protected] ). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. -
Regulation of CRH-Induced Secretion of ACTH and Corticosterone By
European Journal of Endocrinology (2005) 153 R7–R10 ISSN 0804-4643 RAPID COMMUNICATION Regulation of CRH-induced secretion of ACTH and corticosterone by SOM230 in rats A P Silva, P Schoeffter, G Weckbecker, C Bruns and H A Schmid Novartis Institutes for BioMedical Research, Basel, Switzerland (Correspondence should be addressed to H Schmid; Email: [email protected]) Abstract Objective: Adrenocorticotropic hormone (ACTH)-dependent Cushing’s syndrome is biochemically characterized by increased plasma concentrations of ACTH inducing hypersecretion of cortisol. Somatostatin is known to inhibit ACTH secretion, and in vitro data have shown the inhibition of ACTH secretion by agonists activating sst2 and sst5 receptors. The present study aimed to determine the inhibitory effect of the multireceptor ligand SOM230, compared with the sst2-preferring agonist octreotide, on corticotropin-releasing hormone (CRH)-stimulated secretion of ACTH and corticoster- one in rats. Methods: Secretion of ACTH and corticosterone was induced by i.v. application of CRH (0.5 mg/kg) in rats pretreated 1 h before by i.v. application of SOM230 (1, 3, or 10 mg/kg), octreotide (10 mg/kg) or NaCl 0.9%. Results: SOM230 (3 and 10 mg/kg) inhibited CRH-induced ACTH release by 45^3% and 51^2%, respectively, and corticosterone release by 43^5% and 27^16%, respectively. 10 mg/kg of octreotide tended to be less potent at inhibiting ACTH release (34^6% inhibition) and did not alter the secretion of corticosterone. Conclusion: SOM230 has a stronger inhibitory effect on ACTH and corticosterone secretion than octreotide in rats. This difference can be explained by its higher affinity to sst1, sst3 and especially sst5 receptors compared with octreotide. -
Inhibition of Gastrin Release by Secretin Is Mediated by Somatostatin in Cultured Rat Antral Mucosa
Inhibition of gastrin release by secretin is mediated by somatostatin in cultured rat antral mucosa. M M Wolfe, … , G M Reel, J E McGuigan J Clin Invest. 1983;72(5):1586-1593. https://doi.org/10.1172/JCI111117. Research Article Somatostatin-containing cells have been shown to be in close anatomic proximity to gastrin-producing cells in rat antral mucosa. The present studies were directed to examine the effect of secretin on carbachol-stimulated gastrin release and to assess the potential role of somatostatin in mediating this effect. Rat antral mucosa was cultured at 37 degrees C in Krebs-Henseleit buffer, pH 7.4, gassed with 95% O2-5% CO2. After 1 h the culture medium was decanted and mucosal gastrin and somatostatin were extracted. Carbachol (2.5 X 10(-6) M) in the culture medium increased gastrin level in the medium from 14.1 +/- 2.5 to 26.9 +/- 3.0 ng/mg tissue protein (P less than 0.02), and decreased somatostatin-like immunoreactivity in the medium from 1.91 +/- 0.28 to 0.62 +/- 0.12 ng/mg (P less than 0.01) and extracted mucosal somatostatin-like immunoreactivity from 2.60 +/- 0.30 to 1.52 +/- 0.16 ng/mg (P less than 0.001). Rat antral mucosa was then cultured in the presence of secretin to determine its effect on carbachol-stimulated gastrin release. Inclusion of secretin (10(-9)-10(-7) M) inhibited significantly carbachol-stimulated gastrin release into the medium, decreasing gastrin from 26.9 +/- 3.0 to 13.6 +/- 3.2 ng/mg (10(-9) M secretin) (P less than 0.05), to 11.9 +/- 1.7 ng/mg (10(-8) secretin) (P less than 0.02), and to 10.8 +/- 4.0 ng/mg (10(-7) M secretin) (P less than […] Find the latest version: https://jci.me/111117/pdf Inhibition of Gastrin Release by Secretin Is Mediated by Somatostatin in Cultured Rat Antral Mucosa M. -
The Role of Somatostatin in the Regulation of Gonadotropin Secretion in Sheep
Graduate Theses, Dissertations, and Problem Reports 2017 The Role of Somatostatin in the Regulation of Gonadotropin Secretion in Sheep Richard B. McCosh Follow this and additional works at: https://researchrepository.wvu.edu/etd Recommended Citation McCosh, Richard B., "The Role of Somatostatin in the Regulation of Gonadotropin Secretion in Sheep" (2017). Graduate Theses, Dissertations, and Problem Reports. 6194. https://researchrepository.wvu.edu/etd/6194 This Dissertation is protected by copyright and/or related rights. It has been brought to you by the The Research Repository @ WVU with permission from the rights-holder(s). You are free to use this Dissertation in any way that is permitted by the copyright and related rights legislation that applies to your use. For other uses you must obtain permission from the rights-holder(s) directly, unless additional rights are indicated by a Creative Commons license in the record and/ or on the work itself. This Dissertation has been accepted for inclusion in WVU Graduate Theses, Dissertations, and Problem Reports collection by an authorized administrator of The Research Repository @ WVU. For more information, please contact [email protected]. The Role of Somatostatin in the Regulation of Gonadotropin Secretion in Sheep Richard B. McCosh Dissertation submitted to the School of Medicine at West Virginia University in partial fulfillment of the requirements for the degree of Doctor of Philosophy In Biomedical Science Cellular and Integrative Physiology Robert L. Goodman, PhD; Mentor Stanley M. Hileman, PhD; Chair Michael W. Vernon, PhD Steven L. Hardy, PhD Donal C. Skinner, PhD Department of Physiology and Pharmacology Morgantown, West Virginia 2017 Key Words: gonadotropin releasing hormone, luteinizing hormone, somatostatin, kisspeptin, sheep Copyright 2017 Richard B. -
The Role of Corticotropin-Releasing Hormone at Peripheral Nociceptors: Implications for Pain Modulation
biomedicines Review The Role of Corticotropin-Releasing Hormone at Peripheral Nociceptors: Implications for Pain Modulation Haiyan Zheng 1, Ji Yeon Lim 1, Jae Young Seong 1 and Sun Wook Hwang 1,2,* 1 Department of Biomedical Sciences, College of Medicine, Korea University, Seoul 02841, Korea; [email protected] (H.Z.); [email protected] (J.Y.L.); [email protected] (J.Y.S.) 2 Department of Physiology, College of Medicine, Korea University, Seoul 02841, Korea * Correspondence: [email protected]; Tel.: +82-2-2286-1204; Fax: +82-2-925-5492 Received: 12 November 2020; Accepted: 15 December 2020; Published: 17 December 2020 Abstract: Peripheral nociceptors and their synaptic partners utilize neuropeptides for signal transmission. Such communication tunes the excitatory and inhibitory function of nociceptor-based circuits, eventually contributing to pain modulation. Corticotropin-releasing hormone (CRH) is the initiator hormone for the conventional hypothalamic-pituitary-adrenal axis, preparing our body for stress insults. Although knowledge of the expression and functional profiles of CRH and its receptors and the outcomes of their interactions has been actively accumulating for many brain regions, those for nociceptors are still under gradual investigation. Currently, based on the evidence of their expressions in nociceptors and their neighboring components, several hypotheses for possible pain modulations are emerging. Here we overview the historical attention to CRH and its receptors on the peripheral nociception and the recent increases in information regarding their roles in tuning pain signals. We also briefly contemplate the possibility that the stress-response paradigm can be locally intrapolated into intercellular communication that is driven by nociceptor neurons. -
Somatostatin Acts Via a Pertussis Toxin-Sensitive Mechanism on Calcitonin Secretion in C-Cells
Henry Ford Hospital Medical Journal Volume 40 Number 3 Article 35 9-1992 Somatostatin Acts Via a Pertussis Toxin-Sensitive Mechanism on Calcitonin Secretion in C-Cells Angela Zink Hans Scherubl Friedhelm Raue Reinhard Ziegler Follow this and additional works at: https://scholarlycommons.henryford.com/hfhmedjournal Part of the Life Sciences Commons, Medical Specialties Commons, and the Public Health Commons Recommended Citation Zink, Angela; Scherubl, Hans; Raue, Friedhelm; and Ziegler, Reinhard (1992) "Somatostatin Acts Via a Pertussis Toxin-Sensitive Mechanism on Calcitonin Secretion in C-Cells," Henry Ford Hospital Medical Journal : Vol. 40 : No. 3 , 289-292. Available at: https://scholarlycommons.henryford.com/hfhmedjournal/vol40/iss3/35 This Article is brought to you for free and open access by Henry Ford Health System Scholarly Commons. It has been accepted for inclusion in Henry Ford Hospital Medical Journal by an authorized editor of Henry Ford Health System Scholarly Commons. Somatostatin Acts Via a Pertussis Toxin-Sensitive Mechanism on Calcitonin Secretion in C-Cells Angela Zink,* Hans Scherubl,^ Friedhelm Raue,* and Reinhard Ziegler' The effect ofthe somatostatin analog octreotide on cAMP-mediated calcitonin (CT) secretion and cAMP accumulation in C-cells was investigated. Glucagon stimulated cAMP accumulation and CT secretion with a maximal eff'ecl at a concentration oflQ-^M. The cAMP antagonist RpcAMPs blocked the glucagon-induced CT secretion down to control levels. Therefore, no other second messengers seem to he involved in glucagon-stimulated CT secretion. Octreotide in increasing doses (70'' to 10'^ M) inhibited cAMP accumulation and CT secretion with a maximal effect at a concentration of 10'^ (40% and 29% of control values, respectively).